Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Antiretroviral Drug Development and HIV Cure Research"
Deadline for manuscript submissions: 30 April 2020.
Interests: HIV-1 drug development; reverse transcriptase; integrase; endogenous retroviruses
Interests: HIV-1 gene expression and latency; viral RNA structure and function; virus evolution; antiviral therapy; patient-related virus studies
Special Issues and Collections in MDPI journals
Special Issue in Viruses: HIV-1 Latency: Regulation and Reversal
Human immunodeficiency virus type 1 (HIV-1) establishes a persistent infection that results in acquired immunodeficiency syndrome (AIDS) if left untreated. Around 37 million people in the world live with HIV-1, with around 2 million new infections each year. While combined antiretroviral therapy (ART) has been shown to be very effective, inhibiting HIV-1 replication and preventing the development of AIDS, it has to be administered life-long, exposing the patients to possible side-effects. In addition, increasing emergence of resistance to ARV drugs could challenge ART efficacy, especially considering the international effort to reach 40% of HIV-infected people that live in developing countries and are yet to receive treatment. Therefore, despite ART effectiveness, the generation of new drugs against novel targets or with more favorable pharmacokinetics profiles and the development of novel delivery systems has to continue.
Furthermore, ART can limit HIV replication, but treatment interruption triggers a rapid viral rebound, indicating that HIV-1 forms long-lived reservoirs in infected individuals that persist despite decades of suppressive ART. An HIV cure remains a challenge and is not yet within reach. Depletion or silencing of the viral reservoirs has been considered the principal goal of HIV-1 curative strategies. However, very limited successes have been achieved so far, indicating the need for gathering more basic knowledge on HIV-1 latency in order to be able to design more effective therapeutic interventions.
In this Special Issue, we seek reviews and original research articles that discuss the latest developments in HIV drug development and drug delivery and approaches to understand HIV latency. The latter includes the interaction of HIV with human endogenous retroviruses. We hope to accelerate the design of novel strategies to eradicate this viral infection.
Prof. Enzo Tramontano
Prof. Dr. Ben Berkhout
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- HIV latency
- HIV reservoir
- HIV drug development
- HIV drug delivery
- HIV eradication